Heart failure (HF) has been categorized for years according to ejection fraction (EF) into patients with reduced (HFrEF) and preserved EF (HFpEF). In 2016, guidelines from the European Society of Cardiology recognized a third group, initially termed HF with mid-range EF (HFmrEF, originally 40-49%, but now modified to 41-49%), which has more recently been renamed HF with mildly reduced EF. HFmrEF predictably shares features with both HFrEF and HFpEF, but evidence to guide treatment is limited because clinical trials specifically restricted to this patient population have been lacking. The purpose of this Heart Failure Society of America Scientific Statement is to provide a comprehensive review of the epidemiology, clinical characteristics, and pathophysiology and to put forth a clinical framework for the treatment of patients with HFmrEF, for whom randomized trial data are limited.
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269